Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC): Cohort A of the phase 1b/2 KEYNOTE-365 study.
Year: 2019
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Evan Y. Yu, Christophe Massard, Margitta Retz, Ali Tafreshi, Joan Carles, Peter Hammerer, Peter C.C. Fong, Neal D. Shore, Anthony M. Joshua, Mark David Linch, Howard Gurney, Emanuela Romano, Marinela Augustin, Josep M. Piulats, Helen Wu, Charles Schloss, Christian Heinrich Poehlein, Johann S. De Bono
Institutions: University of Washington, Institut Gustave Roussy, TUM Klinikum, Technical University of Munich, University of Wollongong, Vall d'Hebron Hospital Universitari, Klinikum Braunschweig, Auckland City Hospital, Carolina Urologic Research Center, St Vincent's Hospital Sydney, The Kinghorn Cancer Centre, University College London, Macquarie University, Institut Curie, Nuremberg Hospital, Institut Català d'Oncologia, Merck & Co., Inc., Rahway, NJ, USA (United States), Royal Marsden Hospital
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2946862594